MGNX

MacroGenics, Inc.

17.48 USD
+0.44 (+2.58%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MacroGenics, Inc. stock is up 45.55% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Jan 16:58 21 Jun, 2024 10.00 CALL 675 15
02 Feb 20:16 16 Feb, 2024 15.00 CALL 247 100
07 Feb 15:04 19 Jul, 2024 15.00 CALL 54 95
07 Feb 17:23 19 Apr, 2024 2.50 CALL 63 122
07 Feb 17:23 19 Apr, 2024 15.00 CALL 189 67
07 Feb 20:46 20 Dec, 2024 10.00 CALL 27 33
09 Feb 18:42 21 Jun, 2024 20.00 CALL 98 42
12 Feb 15:54 21 Jun, 2024 17.50 PUT 100 0
14 Feb 15:04 20 Dec, 2024 17.50 PUT 100 0
14 Feb 16:11 20 Dec, 2024 17.50 PUT 50 0

About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer. The company also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4.

  • HC Wainwright & Co.
    Wed Feb 14, 06:28
    hold
    downgrade
  • JP Morgan
    Wed Jan 24, 12:17
    buy
    confirm